Results 231 to 240 of about 39,319 (333)

Ibrutinib-Associated Reversible Cardiomyopathy [PDF]

Journal of Oncology Practice, 2019
Chang Fang Chiu, Li Yuan Bai, Shih-Hsin Liang   +2 more
openaire   +2 more sources

Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study

, 2016
Ariela Noy, Sven de Vos, Catherine Thiéblemont, Peter Martin, Christopher R. Flowers, Franck Morschhauser, Graham P. Collins, Shuo Ma, Morton Coleman, Shachar Peles, Stephen D. Smith, Alina Smith, Brian Munneke, Isaiah W. Dimery, Darrin M. Beaupre, Robert W. Chen   +15 more
openalex   +1 more source

Beyond BCL2 (B cell lymphoma) and BTK (Bruton tyrosine kinase) inhibitors: novel agents and resistance mechanisms for chronic lymphocytic leukemia. [PDF]

Discov Oncol
Hays P.
europepmc   +1 more source

Comparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison [PDF]

, 2017
Suzy Van Sanden, Simona Baculea, Joris Diels, Sarah Côté   +3 more
openalex   +1 more source

Number needed to treat and associated cost analysis of zanubrutinib vs ibrutinib in chronic lymphocytic leukemia. [PDF]

J Manag Care Spec Pharm
Chanan-Khan A, Hanna K, Xue M, Massoudi M, Balk M, Gani R, Piran HZ, Yang K.   +7 more
europepmc   +1 more source

CHEMO‐FREE TRIPLET COMBINATION OF TGR‐1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL. [PDF]

, 2017
Loretta J. Nastoupil, Matthew A. Lunning, Julie M. Vose, Marshall T. Schreeder, Tanya Siddiqi, Christopher R. Flowers, Jonathon B. Cohen, Jan A. Burger, William G. Wierda, Susan O’Brien, Peter Sportelli, Hari P. Miskin, Michelle Purdom, Michael Weiss, Nathan Fowler   +14 more
openalex   +1 more source

Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis. [PDF]

Blood Adv
Shadman M, Brown JR, Mohseninejad L, Yang K, Burnett H, Neupane B, Williams R, Lamanna N, O'Brien SM, Tedeschi A, Tam CS.   +10 more
europepmc   +1 more source

Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement [PDF]

, 2017
Doorduijn, J.K. (Jeanette), Hiemcke-Jiwa, L.S. (Laura S.), Huibers, M.M.H. (Manon M. H.), Leguit, P. (Piet), Minnema, M.C. (Monique), Radersma-van Loon, J.H. (Joyce H.), Rood, J.J.M. (Johannes J. M.), Westerweel, J. (Jerry)   +7 more
core   +2 more sources

The effect of ibrutinib on the myeloid cell compartment in CNS lymphoma. [PDF]

Leukemia
Kuehn JC, Neidert NN, Zhang J, Mutter J, Alig S, Klingler C, Hummel F, Ranganathan L, Bleul S, Beck J, Prinz M, Diehn M, Alizadeh A, Duyster J, Sankowski R, Heiland DH, Scherer F.   +16 more
europepmc   +1 more source

Safety and efficacy of single-agent ibrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): A multicenter, open-label, phase 2 study [PDF]

, 2017
Graham P. Collins, Ariela Noy, Sven de Vos, Catherine Thiéblemont, Peter Martin, Christopher R. Flowers, Franck Morschhauser, Shuo Ma, Morton Coleman, Shachar Peles, Stephen D. Smith, Jacqueline C. Barrientos, Ashley M. Smith, Brian Munneke, Isaiah W. Dimery, Darrin M. Beaupre, R. Chen   +16 more
openalex   +1 more source